Follow us on:

Poolbeg Pharma to develop oral vaccine delivery platform (Interview)

Poolbeg Pharma plc (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss a new deal with AnaBio to develop an oral vaccine delivery platform.

Jeremy talks us through the details of today’s announcement, tells us more about the Melioidosis deal, progress made on asset POLB 001 and if we can expect more deals in the coming months.

Poolbeg Pharma (LON: POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables them to develop multiple products faster and more cost effectively than the traditional biotech model.

Poolbeg aspires to become a “one-stop shop” for big pharma to find Phase II ready products for development and commercialisation.

You might also enjoy reading FTSE AIM top share risers: LON:TIME, CER, QED, HERC, POLB, SAE

Find more news, interviews, share price & company profile here for:Poolbeg Pharma plc

Share this interview

Other Interviews

More News

Poolbeg Pharma’s Cathal Friel assumes role of Executive Chairman February 15, 2024
Poolbeg POLB 001 $10 million Market Opportunity for Cancer immunotherapy-induced CRS February 12, 2024
Poolbeg Pharma promising results for POLB 001 in cancer immunotherapy-induced CRS January 17, 2024
Poolbeg Pharma Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI December 20, 2023
Poolbeg Pharma Presented POLB 001 Data at American Society of Hematology December 11, 2023
Poolbeg Pharma Immunomodulator II patent granted in Japan November 21, 2023
Poolbeg Pharma POLB 001 LPS Challenge Trial Data to be Presented at IUIS November 16, 2023
Poolbeg Pharma Appoints Senior Members of Former Amryt Pharma Leadership Team November 9, 2023
Poolbeg Pharma POLB 001 Data to be Presented at American Society of Hematology Annual Meeting November 3, 2023
Poolbeg Pharma’s SAB endorses influenza drug targets identified in AI-led drug discovery programme October 26, 2023

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.